ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Case report: rapid in vivo resistance mechanism shifts in multiple carbapenem-resistant Pseudomonas aeruginosa strains after esophagectomy in an immunocompromised patient: a case report.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Carbapenem-resistant Pseudomonas aeruginosa (CRPA) poses growing therapeutic challenges, particularly in critically ill, immunocompromised patients. More concerning is the rapid shift in resistance mechanisms—such as from non–MBL to metallo-β-lactamase (MBL) producers—within days, which can render initial targeted therapy ineffective. Male in his seventies with esophageal cancer underwent chemoradiotherapy followed by dual immune checkpoint inhibitor therapy, resulting in profound immune dysfunction. After a complex esophagectomy complicated by anastomotic leakage, he developed severe pneumonia while receiving mechanical ventilation, extracorporeal membrane oxygenation (ECMO), and continuous renal replacement (CRRT). Aspergillus fumigatus was first isolated from bronchoalveolar lavage on postoperative day (POD) 4. On POD 12, CRPA with OprD loss and AmpC overexpression was subsequently isolated, as confirmed by antimicrobial susceptibility testing (AST); no other bacterial species were detected. Treatment with ceftazidime/avibactam combined with intravenous amikacin and polymyxin B, together with adjuncts inhaled tobramycin, produced only transient improvement. By POD 15, repeated culture revealed a distinct CRPA isolate producing a VIM-type MBL. Therapy was promptly switched to aztreonam (2 g, q8h) plus ceftazidime/avibactam (2.5 g, q8h), alongside polymyxin B (1 million U, q12h), high-dose amikacin(15 mg/kg), fosfomycin (4 g, q8h), and inhaled tobramycin (300 mg, bid), leading to clinical recovery and microbiologic clearance. This case underscores the need for enhanced mechanism-based surveillance of antimicrobial resistance and adaptive antimicrobial management in high-risk patients. The rapid within-host replacement and emergence of an non-MBL to MBL CRPA highlights the necessity for frequent cultures and rapid carbapenemase testing to guide timely, targeted therapy.
Indexed as
Identifiers
41432845What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.